Espay / Stecher Brain Fables

The Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them
Erscheinungsjahr 2020
ISBN: 978-1-108-89976-5
Verlag: Cambridge University Press
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch

An estimated 80 million people live with a neurodegenerative disease, with this number expected to double by 2050. Despite decades of research and billions in funding, there are no medications that can slow, much less stop, the progress of these diseases. The time to rethink degenerative brain disorders has come. With no biological boundaries between neurodegenerative diseases, illnesses such as Parkinson's and Alzheimer's result from a large spectrum of biological abnormalities, hampering effective treatment. Acclaimed neurologist Dr Alberto Espay and Parkinson's advocate Benjamin Stecher present compelling evidence that these diseases should be targeted according to genetic and molecular signatures rather than clinical diagnoses. There is no Parkinson's or Alzheimer's, simply people with Parkinson's or Alzheimer's. An incredibly important story never before told, Brain Fables is a wakeup call to the scientific community and society, explaining why we have no effective disease-modifying treatments, and how we can get back on track.

Autoren/Hrsg.

Espay, Alberto

Stecher, Benjamin

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Neurologie, Klinische Neurowissenschaft

Inhaltsverzeichnis

Preface; Acknowledgements; 1. The shaky six and the 'second reality'; 2. Pieces of a puzzle?; 3. Disease 'redefinition': a tough pill to swallow; 4. Disease subtypes: the promise and the fallacy; 5. Protein paradox; 6. The fault in our models; 7. Biomarkers: the promise and the fallacy; 8. Lessons from oncology; 9. Symptomatic vs. disease-modifying therapies; 10. The hypothesis that refuses to die; 11. Our living dissonance; 12. The scientific and lay narratives; 13. Challenges viewed from afar; 14. The moonshot: population-based studies of aging; 15. Predictions for the 2020s and beyond; Epilogue. 'When will we have a cure for Parkinson's disease?”; Note added at press time; References; Index.

Über Autor(innen)

Stecher, Benjamin
Benjamin Stecher was diagnosed with Parkinson's Disease aged 29 and has since become actively involved in Parkinson's Disease research and advocacy. He is the founder of Tomorrow Edition, where he has interviewed close to 80 experts in Parkinson's disease, and he sits on several patient advisory boards. He now speaks and consults regularly at academic labs, biotech companies and pharmaceutical giants working to bring better therapies for people diagnosed with Parkinson's disease.

Espay, Alberto
Alberto Espay is Professor of Neurology and Endowed Chair of the University of Cincinnati James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders. He has published over 200 peer-reviewed research articles and leads the first phenotype-agnostic biomarker development program (CCBP), designed to deploy bioassays aiming at matching available therapies with those most likely to benefit, regardless of their clinical diagnosis.